Sepsis in oncology patients is 10 times more common than in patients with non-tumor pathologies. This is due not only to the immunosuppressive effects of tumors, but also to the use of modern anti-tumor therapies. In this particular case, the patient, who was receiving chemotherapy for squamous cell lung cancer, did not show any classical morphological signs of sepsis. However, microcirculatory disorders with severe endothelial dysfunction and the presence of septic bacterial emboli in the vessels of various organs were found. Additionally, clusters of microorganisms were often detected in the stromal tissue of these organs. Alterative changes, such as dystrophy and necrosis, were observed in parenchymal tissues, although there was no perifocal inflammatory infiltration. No hyperplastic changes were seen in the lymphoid tissues.
Anastasia A. Buldakova – resident pathologist of the Department of pathological anatomy with autopsy course Perm State Medical University named after academician E.A. Wagner, trainee-pathologist at the Department of Pathology of Perm Regional Clinical Hospital, Perm, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Genrietta G. Freynd – DSc. (Med.), Professor, Head of the Department of pathological anatomy with autopsy course, Perm State Medical University named after academician E.A. Wagner, Perm, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Irina B. Podrezova – MD, Ph.D. (Med.), senior lecturer of pathological anatomy with autopsy course, Perm State Medical University named after academician E.A. Wagner, acting Head of the Department of Pathology at the Perm Regional Clinical Hospital, Perm, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
1. WHO. Global Report on the epidemiology and burden of sepsis: current Evidence, identifying gaps and future directions. World Health Organization; Geneva, Switzerland: 2020.
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55. DOI: 10.1378/chest.101.6.1644
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250-56. DOI: 10.1097/01.CCM.0000050454.01978.3B
4. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-10. DOI: 10.1001/jama.2016.0287
5. Engoren M, Seelhammer T, Freundlich RE, Maile MD, Sigakis MJG, Schwann TA. A Comparison of Sepsis-2 (systemic inflammatory response syndrome based) to Sepsis-3 (sequential organ failure assessment based) definitions: a multicenter retrospective study. Crit Care Med. 2020;48(9):1258-64 DOI: 10.1097/CCM.0000000000004449
6. Agyeman PKA, Schlapbach LJ, Giannoni E, et al. Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based cohort study. Lancet Child Adolesc Health. 2017;1(2):124-33. DOI: 10.1016/S2352-4642(17)30010-X
7. Kim JS, Kim YJ, Kim WY. Characteristics and clinical outcomes of culture-negative and culture-positive septic shock: a single-center retrospective cohort study. Crit Care. 2021;25(1):11. DOI: 10.1186/s13054-020-03421-4
8. Miller WR, Arias CA. ESKAPE pathogens: anti-microbial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 2024;22(10):598-616. DOI: 10.1038/s41579-024-01054-w
9. Mishnyov OD, Grinberg LM, Zairat’yants OV. Actual problems of the pathology of sepsis: 25 years in search of a consensus. Archive of Pathology. 2016;78(6):3-8 (In Russ). DOI: 10.17116/patol20167863-8
10. Rybakova MG. Sepsis: from systemic inflammatory response syndrome to organ dysfunction. Archive of Pathology. 2021;83(1):67-72. (In Russ.). DOI: 10.17116/patol20218301167
11. Stassi C, Mondello C, Baldino G, Ventura Spagnolo E. Post-mortem investigations for the diagnosis of sepsis: a review of literature. Diagnostics (Basel). 2020;10(10):849. DOI: 10.3390/diagnostics10100849
12. R?b? C, Demontoux L, Pilot T, Ghiringhelli F. Platinum derivatives effects on anticancer immune response. Biomolecules. 2019;10(1):13. DOI: 10.3390/biom10010013
13. Tuano KS, Seth N, Chinen J. Secondary immuno-deficiencies: an overview. Ann Allergy Asthma Immunol. 2021;127(6):617-26. DOI: 10.1016/j.anai.2021.08.413
14. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345-59. DOI: 10.1038/s41568-021-00347-z
15. Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer. 2015;1(1):66-75. DOI: 10.1016/j.trecan.2015.07.008
16. Chirskij VS, Andreeva EA, Yuzvinkevich AK. Morphological features of vascular lesions of the microvas-culature in sepsis. The Scientific Notes of the Pavlov Uni-versity. 2020;27(3):72-9. (In Russ). DOI: 10.24884/1607-4181-2020-27-3-72-79
17. Feig JA, Cina SJ. Evaluation of characteristics associated with acute splenitis (septic spleen) as markers of systemic infection. Arch Pathol Lab Med. 2001;125(7):888-91. DOI:10.5858/2001-125-0888-EOCAWA
18. Mehta S, Gill SE. Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine. J Thorac Dis. 2019;11(1):21-8. DOI: 10.21037/jtd.2018.11.74
19. Maslove DM, Lamontagne F, Marshall JC, Heyland DK. A path to precision in the ICU. Crit Care. 2017;21(1):79. DOI: 10.1186/s13054-017-1653-x
20. Freynd GG, Buldakova AA. Pathogenetic variants of sepsis in oncologicy practice. Ural medical journal 2023;22(2):153-61. (In Russ). DOI: 10.52420/2071-5943-2023-22-2-153-161
The article can be purchased
electronic!
PDF format
700
DOI: 10.14489/lcmp.2025.01.pp.028-037
Article type:
Research Article
Make a request
